Triangulating Evidence for Antihypertensive Drug Class Efficacy on Cardiovascular and Metabolic Outcomes Using Mendelian Randomisation and Colocalisation
Authors: Le Nhu Ngoc , Tran Tran Quoc Bao , McClure John , Gill Dipender , Padmanabhan Sandosh 
Published: August 2024

Background

Current hypertension treatment guidelines typically recommend a standardised approach, which may not account for the inter-individual variability in blood pressure (BP) response or the complex causation of hypertension. This study aims to investigate the heterogeneity of responses to a broad range of antihypertensive drugs across various cardiometabolic and renal outcomes.

Methods

This study employed an integrative approach combining Mendelian randomisation (MR), summary-based MR (SMR), and colocalisation analyses to investigate the impact of BP lowering and the efficacy of seventeen antihypertensive drug classes on the risk of coronary artery disease (CAD), myocardial infarction (MI), atrial fibrillation (AF), heart failure (HF), ischemic stroke, chronic kidney disease (CKD), and type 2 diabetes (T2D). Genetic association and gene expression summary data were obtained from the largest European ancestry GWAS and GTEx v8 for 29 tissues that were broadly relevant to the pathophysiology of cardiovascular outcomes included.

Results

The genetic evidence supported that lower SBP was universally beneficial, causally associated with reduced risks of all studied outcomes. The association of genetically predicted SBP lowering varied significantly depending on the antihypertensive drug class, revealing heterogeneity in their impact on different health outcomes. Novel MR associations were identified, including protective effects of endothelin receptor antagonists, sGC stimulators, and PDE5 inhibitors against CAD (per 10-mmHg decrease in SBP, OR range = 0.197 - 0.348) and ischemic stroke (OR range = 0.218 - 0.686); and sGC stimulators and PDE5 inhibitors against CKD risk (OR range = 0.532 - 0.55). SMR and colocalisation analyses include evidence forGUCY1A3and CAD and MI risk,KCNH2with AF risk, andPDE5Awith CAD risk.

Conclusions

Our results support potential differential impacts of antihypertensive drug classes on cardiometabolic and renal outcomes, underscoring the potential for personalised therapy. Future research should validate these findings across diverse populations and explore the mechanistic pathways between antihypertensive BP modulation and health outcomes.

Clinical Perspective

What is New?

This study utilised Mendelian randomisation, summary-based MR, and colocalisation analyses to explore the differential effects of 17 antihypertensive drug classes on various cardiometabolic and renal outcomes.

Although lower SBP is universally beneficial for reducing risks across all outcomes, the effectiveness of SBP lowering varies significantly by antihypertensive drug class, showing heterogeneity in their impact on different health outcomes.

Newer therapies, including ERAs, PDE5 inhibitors, and sGC stimulators, showed significant protective effects across various outcomes, with ERAs benefiting AF, CAD, MI, and stroke; PDE5 inhibitors protecting against all outcomes except T2D; and sGC stimulators being effective against CAD, MI, stroke, T2D, and CKD.

What are the Clinical Implications?

Understanding the varying impacts of different antihypertensive drug classes on health outcomes can guide more personalised treatment strategies, potentially improving patient outcomes.

These results not only validate the clinical relevance of existing antihypertensive therapies but also highlight new therapeutic targets, such asGUCY1A3andPDE5A, for further exploration.

Future research should focus on validating these results across diverse populations to refine hypertension management strategies and implement personalised treatment in clinical practice.